Bicycle Therapeutics (BCYC) Cash from Operations (2018 - 2026)
Bicycle Therapeutics (BCYC) posted Cash from Operations of 65925000.0 for Q1 2026, down 240.77% on a QoQ basis from 19346000.0 in Q4 2025, and up 23.67% year-over-year from 53306579.13 in Q1 2025.
Bicycle Therapeutics (BCYC) Cash from Operations (2018 - 2026) Analysis & Trends
Bicycle Therapeutics' Cash from Operations history runs 9 years deep, the most recent figure standing at 65925000.0 for Q1 2026.
- Quarterly Cash from Operations rose 23.67% year-over-year to 65925000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 229230000.0 (down 27.19% YoY) and the FY2025 annual result came in at 249675000.0, down 51.57% from the prior year.
- Cash from Operations was 65925000.0 for Q1 2026 at Bicycle Therapeutics, down from 19346000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 34096000.0 in Q2 2023 and bottomed at 86370000.0 in Q1 2025.
- A 5-year average of 36886058.82 and a median of 39832000.0 in 2024 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2023 — Cash from Operations surged 244.9% — and 2024, when it slumped 3786.05%.
- Bicycle Therapeutics' Cash from Operations stood at 30309000.0 in 2022, then plunged by 56.02% to 47288000.0 in 2023, then jumped by 80.13% to 9396000.0 in 2024, then plunged by 105.9% to 19346000.0 in 2025, then plunged by 240.77% to 65925000.0 in 2026.
- Business Quant data shows BCYC's Cash from Operations at 65925000.0 in Q1 2026, 19346000.0 in Q4 2025, and 71173000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | Bicycle Therapeutics | 289.88 Mn | 289.88 Mn | - | -65.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -65.93 Mn |
| Mar 31, 2026 | -65.93 Mn |
| Dec 31, 2025 | -19.35 Mn |
| Dec 31, 2025 | -19.35 Mn |
| Sep 30, 2025 | -71.17 Mn |
| Sep 30, 2025 | -71.17 Mn |
| Jun 30, 2025 | -72.79 Mn |
| Jun 30, 2025 | -72.79 Mn |
| Mar 31, 2025 | -86.37 Mn |
| Mar 31, 2025 | -86.37 Mn |
| Dec 31, 2024 | -9.40 Mn |
| Dec 31, 2024 | -9.40 Mn |
| Sep 30, 2024 | -39.83 Mn |
| Sep 30, 2024 | -39.83 Mn |
| Jun 30, 2024 | -44.63 Mn |
| Jun 30, 2024 | -44.63 Mn |
| Mar 31, 2024 | -70.87 Mn |
| Mar 31, 2024 | -70.87 Mn |
| Dec 31, 2023 | -47.29 Mn |
| Dec 31, 2023 | -47.29 Mn |